Jason R. Kelly Sells 103,765 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) insider Jason R. Kelly sold 103,765 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $2.10, for a total value of $217,906.50. Following the sale, the insider now owns 20,519,888 shares in the company, valued at approximately $43,091,764.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ginkgo Bioworks Price Performance

DNA stock opened at $1.98 on Friday. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $1.94 and a twelve month high of $12.48. The business’s 50-day simple moving average is $2.71 and its 200 day simple moving average is $2.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.71 and a quick ratio of 11.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lincoln National Corp bought a new position in shares of Ginkgo Bioworks in the second quarter valued at approximately $26,000. Itau Unibanco Holding S.A. acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth $30,000. Atria Wealth Solutions Inc. acquired a new stake in Ginkgo Bioworks during the 2nd quarter worth $30,000. Lake Street Financial LLC acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth $31,000. Finally, Avantax Advisory Services Inc. acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth $31,000. Institutional investors own 53.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. BTIG Research dropped their price target on Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. Morgan Stanley initiated coverage on Ginkgo Bioworks in a report on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 price objective for the company. Finally, Raymond James decreased their price target on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus price target of $5.91.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Further Reading

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.